California Public Employees Retirement System raised its stake in Epizyme Inc (NASDAQ:EPZM) by 21.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,500 shares of the biopharmaceutical company’s stock after purchasing an additional 22,700 shares during the quarter. California Public Employees Retirement System owned about 0.16% of Epizyme worth $779,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Quantamental Technologies LLC purchased a new stake in shares of Epizyme in the fourth quarter worth about $43,000. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Epizyme in the fourth quarter valued at about $76,000. Shell Asset Management Co. acquired a new stake in shares of Epizyme in the third quarter valued at about $198,000. MetLife Investment Advisors LLC grew its stake in shares of Epizyme by 50.5% in the third quarter. MetLife Investment Advisors LLC now owns 37,738 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 12,663 shares in the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Epizyme by 70.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 50,838 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 20,983 shares during the period. Institutional investors own 72.63% of the company’s stock.
Several equities analysts recently commented on EPZM shares. Oppenheimer set a $27.00 price target on Epizyme and gave the stock a “buy” rating in a research report on Friday, January 4th. BidaskClub upgraded shares of Epizyme from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 27th. Cowen reissued a “buy” rating and set a $18.00 target price on shares of Epizyme in a research report on Tuesday, February 26th. Leerink Swann raised shares of Epizyme from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Monday, January 7th. Finally, ValuEngine downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $18.40.
NASDAQ:EPZM opened at $13.64 on Friday. Epizyme Inc has a one year low of $5.14 and a one year high of $18.70. The stock has a market capitalization of $1.17 billion, a P/E ratio of -7.93 and a beta of 3.14.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.17. Analysts forecast that Epizyme Inc will post -2.18 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “California Public Employees Retirement System Grows Holdings in Epizyme Inc (EPZM)” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.thestockobserver.com/2019/04/07/california-public-employees-retirement-system-grows-holdings-in-epizyme-inc-epzm.html.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Article: What does RSI mean?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.